Nyxoah heads into its third-quarter report with an awkward gap between what its leading indicators suggested last quarter and what management has since told investors. On the summer call, the company pointed to doubling active accounts, a swelling prior-authorization pipeline and a freshly repaired balance sheet. Since then it has cut its 2026 revenue outlook to $37.0 million to $39.25 million, down from $40.37 million to $44.85 million. The report after the close on November 5 needs to explain why a funnel that looked so healthy is converting into revenue more slowly than planned.

Wall Street expects a loss of $0.24 per share on revenue of $11.1 million. That would be nearly five times the $2.3 million booked a year ago, but year-over-year growth is less meaningful for a company still early in its US launch. The more useful comparison is sequential: $11.1 million would be roughly 25% above the second quarter's $8.9 million, a faster pace than the 22% US growth Nyxoah delivered last quarter. The sharp improvement from last quarter's $0.67 loss likely reflects, at least in part, a larger share count following the $110 million raise, so per-share figures may say less about operating progress than usual. The bigger problem is the full-year consensus of $43.9 million, which sits well above the top of the new guidance range. Those estimates have not caught up. With first-half revenue in the mid-teens of millions of dollars, the revised range implies only about $21 million to $23 million for the back half. A third quarter at consensus would leave little room for fourth-quarter growth, so either the quarterly estimate comes down or management signals that its new range is conservative.

The guidance cut confirms the warning signs from last quarter. Second-quarter US growth already fell short of the 25% to 30% management had projected. The company also stopped repeating its earlier targets for low-40s sequential growth in the third quarter and about 50% in the fourth. The key question is where the conversion is breaking down. Last quarter, Nyxoah entered the period with 427 patients in prior authorization, up 77% from the prior quarter, along with a 100% approval rate. If that backlog did not turn into implants, investors need to know whether the cause is scheduling, surgeon capacity or slow ramp at the 89 accounts opened in the second quarter. Blended market share stuck near 15% supports the slow-ramp explanation. Steady gains in surgeons trained and active accounts, plus evidence that older accounts are moving toward the 44% share seen at the longest-standing site, would suggest a timing issue rather than weak demand.

Margins and spending are the other tests. Gross margin recovered to 60% after yield problems, and management described a path back to the mid-60s. Another step up would show the manufacturing problems are fixed. Quarterly cash burn of about €20 million is manageable against roughly €97.8 million in cash, but slower revenue makes the planned expansion from 40 to 55 sales territories harder to justify. Updates on the PMA supplement for complete concentric collapse patients, which the company targeted for late third or early fourth quarter, would also bolster the longer-term story.

The market has already punished the stock. Shares are down 33% since the last report while the S&P 500 was flat. At $0.91, the stock sits near the bottom of its post-earnings range of $0.80 to $1.83 and far below its 200-day moving average of $2.58. Sentiment is still bearish but less so, easing to 65.3% from 79.7%, which suggests some investors think the reset is priced in.

Ultimately, this report hinges on whether the lowered guidance looks like a realistic floor or the start of further cuts. Third-quarter revenue near $11 million, strong conversion of the authorization backlog and a confident fourth-quarter outlook would support the view that the launch is slower but still sound. Another shortfall would raise doubts about how well the company's leading indicators predict actual revenue.